RenovoRx, Inc. (RNXT)
1.275
0.00 (0.00%)
USD |
NASDAQ |
Oct 12, 13:00
RenovoRx Gross Profit Margin (Quarterly) : 84.27% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 84.27% |
| March 31, 2026 | 85.08% |
| December 31, 2025 | 88.24% |
| September 30, 2025 | 80.08% |
| Date | Value |
|---|---|
| June 30, 2025 | 63.98% |
| March 31, 2025 | 52.28% |
| December 31, 2024 | 0.00% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Enanta Pharmaceuticals, Inc. | 91.75% |
| Travere Therapeutics, Inc. | 96.22% |
| REGENXBIO, Inc. | 95.56% |
| Krystal Biotech, Inc. | 93.46% |
| ACADIA Pharmaceuticals, Inc. | 90.81% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -138.4% |
| Return on Assets | -105.1% |
| Return on Invested Capital | -134.5% |
| Profit Margin (Quarterly) | -320.2% |
| Operating Margin (Quarterly) | -368.4% |
| Return on Net Operating Assets | -1.03K% |